Effect of vigabatrin on the pharmacokinetics of carbamazepine
Article
Overview
Research
Identity
Additional Document Info
View All
Overview
abstract
Objective: To evaluate a possible interaction between vigabatrin and carbamazepine in epileptic patients. Methods: Steady-state serum concentrations of carbamazepine with and without vigabatrin were compared. The study group consisted of 15 patients (eight females, seven males, and mean age 31 ± 12 years), with refractory partial epilepsy. They received vigabatrin as add-on therapy. Patients received carbamazepine monotherapy for at least 6 months and the carbamazepine-vigabatrin combination for at least 3 months. Blood samples were obtained in the morning, before the first daily dose and the carbamazepine plasma concentrations were analysed by fluorescence polarization immunoassay (TDx System). Results: No statistically significant differences were found in mean carbamazepine daily dose. Mean trough concentrations were 7.9 ± 1.4 μg/mL with carbamazepine alone, and 6.5 ± 2.0 μg/mL with carbamazepine-vigabatrin association (P < 0.03). The mean values of pharmacokinetic parameters were: level/dose ratio (L/D) = 0.59 ± 0.20 vs. 0.45 ± 0.15 (P < 0.05) and plasma clearance (Cl) = 78.5 ± 25.8 vs. 105.8 ± 38.9 mL/h/kg (P < 0.05), with carbamazepine alone and carbamazepine-vigabatrin combination, respectively. Conclusion: Vigabatrin produced a statistically significant increase in the plasma clearance of carbamazepine when the two drugs were given simultaneously.
